BridgeBio (BBIO) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 22, 2026, to be held virtually, with voting on key proposals including director elections, executive compensation, auditor ratification, and an amendment to the stock option plan.

• Shareholders of record as of April 23, 2026, are entitled to vote, with 195,806,242 shares outstanding and eligible.

• Voting can be conducted online, by phone, mail, or during the virtual meeting, with detailed instructions provided.

Voting matters and shareholder proposals

• Election of three Class I directors to serve until the annual meeting following the year ending December 31, 2028.

• Advisory vote to approve executive compensation (say-on-pay) and a separate advisory vote on the frequency of future say-on-pay votes.

• Ratification of Deloitte & Touche LLP as independent auditor for fiscal year ending December 31, 2026.

• Approval of an amendment to the 2021 Stock Option and Incentive Plan to increase reserved shares by 2,000,000.

• Procedures for shareholder proposals and director nominations for the 2027 annual meeting are outlined, with specific deadlines and requirements.

Board of directors and corporate governance

• The board is divided into three classes with staggered three-year terms; after the meeting, the board will have 13 members.

• Independence is maintained, with all but three directors considered independent under Nasdaq and SEC rules.

• Committees include Audit, Compensation, and Nominating and Corporate Governance, each with defined responsibilities and independent membership.

• Director compensation includes cash retainers and equity awards, with updated policies effective January 1, 2026.